Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Initial FLAG-Ida outperforms 7+3 for high-risk AML

Key clinical point: The FLAG-Ida regimen showed better results for high-risk patients with acute myelogenous leukemia (AML), compared with 7+3.

Major finding: The 3-year postremission overall survival was significantly better for patients receiving FLAG-Ida at 54%, compared with 39% for 7+3 treatment.

Study details: A retrospective study of 304 consecutive AML patients, with nonfavorable risk.

Disclosures: There was no outside funding for this research and the authors reported that they had no relevant financial conflicts.


Solh MM et al. Leuk Res. 2020 Feb 14. doi: 10.1016/j.leukres.2020.106318.